Juvenile Myelomonocytic Leukemia (JMML)Symptoms, Doctors, Treatments, Advances & More
Learn About Juvenile Myelomonocytic Leukemia (JMML)
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Franco Locatelli practices practicing medicine in Rome, Italy. Mr. Locatelli is rated as an Elite expert by MediFind in the treatment of Juvenile Myelomonocytic Leukemia (JMML). He is also highly rated in 69 other conditions, according to our data. His clinical expertise encompasses Acute Lymphoblastic Leukemia (ALL), Leukemia, Graft Versus Host Disease (GvHD), Bone Marrow Transplant, and Splenectomy.
Marco Zecca practices practicing medicine in Pavia, Italy. Mr. Zecca is rated as an Elite expert by MediFind in the treatment of Juvenile Myelomonocytic Leukemia (JMML). He is also highly rated in 41 other conditions, according to our data. His clinical expertise encompasses Juvenile Myelomonocytic Leukemia (JMML), Anemia, Graft Versus Host Disease (GvHD), Bone Marrow Transplant, and Bone Graft.
Charlotte Niemeyer practices practicing medicine in Freiburg, Germany. Ms. Niemeyer is rated as an Elite expert by MediFind in the treatment of Juvenile Myelomonocytic Leukemia (JMML). She is also highly rated in 26 other conditions, according to our data. Her clinical expertise encompasses Juvenile Myelomonocytic Leukemia (JMML), Aase Syndrome, Pure Red Cell Aplasia, Aplastic Anemia, and Bone Marrow Transplant.
Summary: This clinical trial will test the safety and efficacy of combining trametinib and azacitidine in patients with juvenile myelomonocytic leukemia (JMML). Newly diagnosed lower-risk JMML patients will receive trametinib and azacitidine. High-risk JMML patients will receive trametinib, azacitidine, fludarabine, and cytarabine.
Summary: This phase I trial tests the safety, side effects, and best dose of imetelstat in combination with fludarabine and cytarabine in treating patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) or juvenile myelomonocytic leukemia (JMML) that has not responded to previous treatment (refractory) or that has come back after a period of improvement (recurrent). Imetelstat may stop t...